Jon Blaskovich
Chief Tech/Sci/R&D Officer chez BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Profil
M. Jon Blaskovich est directeur des technologies de l'information chez Biohaven Pharmaceutical Holding Co. Ltd. Il a obtenu son diplôme de premier cycle à l'Institut de technologie de Rochester.
Postes actifs de Jon Blaskovich
| Sociétés | Poste | Début |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Tech/Sci/R&D Officer | - |
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Jon Blaskovich
| Sociétés | Poste | Fin |
|---|---|---|
Epsilon Data Management LLC
 Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Chief Tech/Sci/R&D Officer | - |
Formation de Jon Blaskovich
| Rochester Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOHAVEN LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Epsilon Data Management LLC
Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
